Altered regulation of tyrosine kinase receptors (RTKs) is frequent in solid tumors and it is often associated with the acquisition of an aggressive phenotype. Thus, therapies targeting these receptors have been proposed as molecular approaches to treat human cancers. The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF), controls genetic programs leading to cell growth, invasion and protection from apoptosis. Germline mutations of MET in patients affected by Hereditary Papillary Renal Carcinomas (HPRC) have provided strong genetic evidences for its role in human malignancies; moreover constitutive activation of this receptor, as consequence of different mechanisms such as overexpression, autocrine stimulation or point mutations, is frequent in sporadic cancers. Several strategies to block the activation of MET are under development, such as the use of tyrosine kinase inhibitors or monoclonal antibodies and some of these compounds have already been used in clinical trials. In this review we will discuss the molecular mechanisms underlying MET involvement in tumorigenesis and present preclinical and clinical data obtained with compounds aimed at targeting MET in the frame of cancer therapy.

Molecular cancer therapy: can our expectation be met?

MIGLIORE, Cristina;GIORDANO, Silvia
2008

Abstract

Altered regulation of tyrosine kinase receptors (RTKs) is frequent in solid tumors and it is often associated with the acquisition of an aggressive phenotype. Thus, therapies targeting these receptors have been proposed as molecular approaches to treat human cancers. The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF), controls genetic programs leading to cell growth, invasion and protection from apoptosis. Germline mutations of MET in patients affected by Hereditary Papillary Renal Carcinomas (HPRC) have provided strong genetic evidences for its role in human malignancies; moreover constitutive activation of this receptor, as consequence of different mechanisms such as overexpression, autocrine stimulation or point mutations, is frequent in sporadic cancers. Several strategies to block the activation of MET are under development, such as the use of tyrosine kinase inhibitors or monoclonal antibodies and some of these compounds have already been used in clinical trials. In this review we will discuss the molecular mechanisms underlying MET involvement in tumorigenesis and present preclinical and clinical data obtained with compounds aimed at targeting MET in the frame of cancer therapy.
44
5
641
651
Tyrosine kinase receptors; MET/Hepatocyte Growth Factor Receptor; Targeted therapy; kinase inhibitors; clinical trials.
Migliore C; Giordano S.
File in questo prodotto:
File Dimensione Formato  
2008_Molecular cancer therapy. Can our expectation be MET.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 608.95 kB
Formato Adobe PDF
608.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/55038
Citazioni
  • ???jsp.display-item.citation.pmc??? 40
  • Scopus 108
  • ???jsp.display-item.citation.isi??? 101
social impact